Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,444 | -19,381 | -13,676 | -13,592 | -12,292 |
| Depreciation Amortization | -1,304 | -1,193 | 14 | 185 | 17 |
| Accounts receivable | 133 | -287 | 48 | 210 | 483 |
| Other Working Capital | 1,512 | 93 | 585 | -461 | 1,195 |
| Other Operating Activity | 2,027 | 2,040 | 1,518 | 1,406 | 1,412 |
| Operating Cash Flow | $-22,076 | $-18,728 | $-11,511 | $-12,252 | $-9,185 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 8,589 | -18,275 | 11,619 | -20,517 | -16,103 |
| PPE Investments | -25 | -24 | -81 | -20 | -31 |
| Investing Cash Flow | $8,564 | $-18,299 | $11,538 | $-20,537 | $-16,134 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -9 | -6 | -6 | -6 | -5 |
| Common Stock Issued | 12,003 | 36,848 | N/A | 30,093 | 28,850 |
| Financing Cash Flow | $11,994 | $36,842 | $-6 | $30,087 | $28,845 |
| Beginning Cash Position | 4,543 | 4,728 | 4,707 | 7,409 | 3,883 |
| End Cash Position | 3,025 | 4,543 | 4,728 | 4,707 | 7,409 |
| Net Cash Flow | $-1,518 | $-185 | $21 | $-2,702 | $3,526 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,076 | -18,728 | -11,511 | -12,252 | -9,185 |
| Capital Expenditure | -25 | -24 | -81 | -22 | -47 |
| Free Cash Flow | -22,101 | -18,752 | -11,592 | -12,274 | -9,232 |